Deerfield
About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More
---
Investment

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More
---
Information

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---
Philanthropy

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
---
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More
---
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

---
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
---
Cure Campus

Cure is a 12-story innovations campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Meet the Cure Team Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Cure Symposium Calendar

Bridge Medicines Appoints Louis M. Renzetti, Ph.D., As Chief Scientific Officer

New York, NY – April 3, 2018 ‐ Bridge Medicines, a pioneering drug discovery company focused on advancing promising early technologies from concept to clinic, announced today the appointment of Louis M. Renzetti, Ph.D., as Chief Scientific Officer (CSO).

Bridge Medicines, launched by Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine, in partnership with Takeda Pharmaceutical Company Ltd., Deerfield Management and Bay City Capital, is a groundbreaking initiative that extends the work of the independent, non‐profit Tri‐Institutional Therapeutics Discovery Institute (Tri‐I TDI). Tri‐I TDI, also a collaborative venture of the three academic institutions, in partnership with Takeda, is working on approximately 50 early‐stage drug discovery projects spanning therapeutic areas that include infectious disease, oncology, neuropsychiatry and rare diseases. As CSO of Bridge Medicines, Dr. Renzetti will be responsible for scientific oversight for R&D programs within Bridge Medicines, building a portfolio of early‐stage drug discovery projects and positioning these programs for entry into the clinic.

“We are thrilled to bring such a talented drug discovery expert as Louis into the role of CSO at Bridge Medicines,” said William Polvino, CEO of Bridge Medicines. “Louis is a rigorously trained scientist and an experienced drug developer. His skills in identifying promising scientific targets and driving toward successful clinical products will be a great asset to the mission of Bridge Medicines, the Tri‐I TDI, and the three institutions.”

Dr. Renzetti said, “Bridge Medicines is a unique opportunity to transform the breakthrough research done at Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, and the Tri‐I TDI into valuable medicines for patients. I am excited to join Bill and the team and look forward to working with the highly talented investigators within the Tri‐Institutional community.”

Dr. Renzetti has more than 25 years of experience in biopharma, encompassing all aspects of drug discovery and early development. Most recently, he served as Chief Research and Early Development Officer for Gotham Therapeutics, a New York‐based start‐up. Prior to Gotham, Dr. Renzetti served as SVP of Drug Discovery and Early Development at X‐Rx, Inc., where he led the company’s efforts to develop small molecule inhibitors of autotaxin to treat fibrotic diseases, a program subsequently partnered with Gilead. Dr. Renzetti spent much of his drug discovery career at Roche. He was the champion and leader of the RNA Therapeutics division and collaboration with Alnylam. He served as the Disease Biology Area Head for Inflammation, was VP of Respiratory and Inflammation, and head of Discovery Pharmacology. Dr. Renzetti has advanced numerous programs to clinical candidacy and into the clinic. He earned his doctorate in Physiology from the Lewis Katz School of Medicine at Temple University and his Bachelor of Arts Degree from the University of Pennsylvania. Dr. Renzetti completed his post‐doctoral training in Pharmacology at ICI Pharmaceuticals. He has authored more than 30 publications.

About Bridge Medicines

Bridge Medicines is a pioneering drug‐discovery company focused on advancing promising early technologies in major academic institutions from human proof‐of‐concept to clinical development. Launched by Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine and Takeda Pharmaceutical Company Ltd., in partnership with Deerfield Management and Bay City Capital, Bridge Medicines is a groundbreaking initiative that provides an unbroken, fully funded and professionally staffed path from discovery to drug candidate.

Contacts

Karen Heidelberger
Deerfield Management
[email protected]
(212) 551‐1600

Carl S. Goldfischer, MD
Bay City Capital, LLC
[email protected]
(415) 835‐9385